FIELD: medicine.
SUBSTANCE: method of early solid malignant disease staging (at the stage of provisional clinical diagnosis) by cell number with stable ontogenetic disorders detected in patient's peripheral blood lymphocytes by quantitative and qualitative analysis of stable chromosomal and genomic disorders in metaphase plates from patient's peripheral blood lymphocytes.
EFFECT: method enables following disease change shift in response to treatment and determining clinical effectiveness.
5 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING LENGTH OF ADJUVANT THERAPY IN SKIN MELANOMA | 2009 |
|
RU2412641C1 |
| PROGNOSIS METHOD FOR DISEASE PROGRESSION IN PATIENTS WITH GASTROINTESTINAL CANCER AFTER TREATMENT | 2021 |
|
RU2758079C2 |
| METHOD OF TREATING ONCOLOGICAL DISEASES | 2020 |
|
RU2741701C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF ADJUVANT INTERFERON THERAPY OF SKIN MELANOMA | 2019 |
|
RU2722403C1 |
| METHOD FOR DETECTION OF PRIMARY REFRACTORY FORM OF MULTIPLE MYELOMA AT THE DISEASE ONSET | 2020 |
|
RU2749612C1 |
| METHOD FOR PREDICTION OF DISEASE OUTCOME IN PATIENTS WITH GASTRIC CANCER AFTER SURGICAL MANAGEMENT | 2018 |
|
RU2696054C1 |
| METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 1999 |
|
RU2157998C1 |
| METHOD OF TREATING ONCOLOGICAL DISEASES | 2008 |
|
RU2379055C1 |
| METHOD OF PREDICTION OF CLINICAL COURSE OF UVEA MELANOMA BASED ON APOPTHOSIS MARKER Bax | 2002 |
|
RU2208790C1 |
| METHOD OF CALCULATION OF FORECAST FOR EARLY DEVELOPMENT OF SKIN MELANOMA | 2017 |
|
RU2643761C1 |
